Generali Asset Management SPA SGR Makes New $1.18 Million Investment in DexCom, Inc. (NASDAQ:DXCM)

Generali Asset Management SPA SGR purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 15,111 shares of the medical device company’s stock, valued at approximately $1,175,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc bought a new stake in DexCom during the fourth quarter worth about $25,000. Private Trust Co. NA lifted its stake in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares during the last quarter. Larson Financial Group LLC lifted its stake in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after purchasing an additional 137 shares during the last quarter. Heck Capital Advisors LLC bought a new stake in DexCom during the fourth quarter worth about $38,000. Finally, SBI Securities Co. Ltd. bought a new stake in DexCom during the fourth quarter worth about $49,000. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Up 2.4 %

DXCM stock opened at $75.11 on Friday. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The business’s 50 day moving average price is $83.41 and its two-hundred day moving average price is $76.92. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company has a market capitalization of $29.35 billion, a price-to-earnings ratio of 52.52, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DXCM has been the subject of several research analyst reports. Canaccord Genuity Group lifted their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Morgan Stanley boosted their target price on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Citigroup boosted their target price on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $99.82.

Insider Buying and Selling

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. This represents a 2.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Michael Jon Brown sold 13,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the sale, the executive vice president now owns 105,602 shares in the company, valued at $7,432,268.76. The trade was a 10.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 105,009 shares of company stock worth $8,044,178 in the last 90 days. Insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.